These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 16022172)

  • 21. Bayesian optimal adaptive designs for delayed-response dose-finding studies.
    Li W; Fu H
    J Biopharm Stat; 2011 Sep; 21(5):888-901. PubMed ID: 21830921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-escalation designs in oncology: ADEPT and the CRM.
    Shu J; O'Quigley J
    Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statistical consideration of adaptive methods in clinical development.
    Chow SC; Chang M; Pong A
    J Biopharm Stat; 2005; 15(4):575-91. PubMed ID: 16022164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Bayesian approach for dose-escalation in a Phase I clinical trial incorporating pharmacodynamic endpoints.
    Whitehead J; Zhou Y; Hampson L; Ledent E; Pereira A
    J Biopharm Stat; 2007; 17(6):1117-29. PubMed ID: 18027220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical analysis for two-stage seamless design with different study endpoints.
    Chow SC; Lu Q; Tse SK
    J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
    Thomas N
    J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continual reassessment method: a likelihood approach.
    O'Quigley J; Shen LZ
    Biometrics; 1996 Jun; 52(2):673-84. PubMed ID: 8672707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
    Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
    Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Bayesian design and analysis for dose-response using informative prior information.
    Smith MK; Marshall S
    J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian adaptive clinical trials: a dream for statisticians only?
    Chevret S
    Stat Med; 2012 May; 31(11-12):1002-13. PubMed ID: 21905067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis strategies for adaptive designs with multiple endpoints.
    Chang M; Chow SC
    J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian population approaches to the analysis of dose escalation studies.
    Russu A; De Nicolao G; Poggesi I; Neve M; Gomeni R
    Comput Methods Programs Biomed; 2012 Aug; 107(2):189-201. PubMed ID: 21764475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovative approaches to clinical development and trial design.
    Orloff JJ; Stanski D
    Ann Ist Super Sanita; 2011; 47(1):8-13. PubMed ID: 21430331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective robustness of the continual reassessment method.
    O'Quigley J; Zohar S
    J Biopharm Stat; 2010 Sep; 20(5):1013-25. PubMed ID: 20721788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian optimal designs for a quantal dose-response study with potentially missing observations.
    Baek I; Zhu W; Wu X; Wong WK
    J Biopharm Stat; 2006; 16(5):679-93. PubMed ID: 17037265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.